Morgan Stanley and Perella Weinberg have launched the MS Perella Weinberg Partners Tōkum Long/Short Healthcare UCITS Fund on the investment bank’s UCITS Irish umbrella, FundLogic Alternatives. 
 
The new fund will offer access to a global long/short equity strategy focused on the healthcare industry (including biotechnologies, pharmaceuticals and companies engaged in the medical technology and services businesses) and will seek attractive risk-adjusted returns.FundLogic is the platform brand name for Morgan Stanley fund solutions launched in 2006.
 

“The MS Perella Weinberg Partners Tōkum Long/Short Healthcare UCITS Fund will leverage our team’s bottom-up fundamental research process to identify, within the healthcare industry’s rapidly evolving technological and regulatory frameworks, material levers impacting businesses positively or negatively over a two to four-year horizon, said Emile Westergaard, portfolio manager of the fund. “We strongly believe our unique portfolio construction matrix, which has been developed to take into account a multi-factored set of inputs guided by absolute return objectives, implied volatility targets and liquidity requirements, fits well within the UCITS framework.”

David Armstrong, Managing Director and Global Head of the Fund and Fund-Linked business at Morgan Stanley commented: “In less than a year of running our FundLogic Alternatives Platform, we have successfully put to market a wide range of alternative strategies in a UCITS format, with programs covering long/short equity, event-driven and convertible arbitrage. The launch of the MS Perella Weinberg Partners Tōkum Long/Short Healthcare UCITS Fund adds an outstanding option to gain exposure to a new sector focused strategy. We look forward to our partnership with Perella Weinberg Partners to offer investors a new route to capture the evolutions of the healthcare industry.”

Greth Lester, responsible for overseeing Perella Weinberg Partners’ investor relations and asset management business in Europe, commented: “We are delighted to collaborate with Morgan Stanley, one of the leading providers of alternative strategies in a UCITS format. Morgan Stanley has an impressive track-record of successfully launching alternative UCITS strategies, which we believe will further enhance our European presence and provide new opportunities to investors in search of an attractive absolute return profile focusing on long/short healthcare opportunities.”